A B S T R A C T The clinical and metabolic effects of porcine calcitonin were assessed in six patients with Paget's disease and two patients with osteoporosis under metabolic balance conditions. The administration of calcitonin for 4-17 wk resulted in an amelioration of the clinical phenomena associated with Paget's disease, including bone pain, increased skeletal vascularity, congestive heart failure, and neurologic deficits secondary to skeletal impingement. The major metabolic effects of calcitonin in Paget's disease included the induction of positive calcium balance of +50 to +240 mg/day, reduction in hyperphosphatasia and hydroxyprolinuria of 15 to 60%, and a deceleration of radiocalcium turnover by 12 to 46%. Natriuresis, phosphaturia, and reduced urinary calcium excretion were observed, whereas sustained hypocalcemia and hypophosphatemia did not occur. The administration of porcine calcitonin was not associated with adverse objective or subjective reactions, toxic effects, or allergic phenomena. There was no evidence of antibody formation or loss of therapeutic potency. Although the response of individual patients with Paget's disease varied widely, the data indicate that calcitonin, presumably through its skeletal anti-resorptive action, is able to reduce skeletal turnover and volume in Paget's disease, and thereby improve the associated clinical and metabolic 'abnormalities. Long term therapeutic studies in progress suggest that prolonged periods of control of the generalized condition may be feasible.
INTRODUCTION
Paget's disease of the skeleton is associated with extreme acceleration of the rates of bone formation and resorption. The resorption process is generally regarded to be a primary consequence of the disease whereas the increased rate of bone formation is considered a secondary event (1) . The increased skeletal turnover results in microscopic and gross distortions of bone architecture, and increased vascularity of the skeleton. Important clinical consequences include bone pain and deformity, pathologic fractures, neurologic deficits, and congestive heart failure. Calcitonin, the polypeptide hormone of ultimobranchial and thyroid parafollicular cell origin, is a powerful in vivo and in vitro inhibitor of bone resorption (2) . The present metabolic and clinical study was undertaken to ascertain whether calcitonin is capable of inhibiting the pathologic bone resorption of generalized Paget's disease.
METHODS
Six patients with generalized Paget's disease, ranging in age from 55 to 75 yr, were admitted to the hospital for study during treatment with porcine calcitonin. Four of the patients had not received previous therapy for bone disease. One patient (C. E. L.) received sodium fluoride in the distant past and phosphate therapy for 2 yr until 2 wk before admission to the study. One patient (A. V.) received sodium fluoride for 5 wk but discontinued the drug 3, wk before admission. For comparative purposes, two women, ages 56 and 80 yr with postmenopausal and senile osteoporosis, respectively, were studied under identical conditions. One patient (A. D.) had received 2 mg of diethylstilbestrol daily and 100 mg of testosterone cyprionate weekly for 3 yr without clinical benefit; these drugs were continued during study. The second patient (J. M.) discontinued daily use of sodium fluoride (20 mg) and Premarin, Ayerst Laboratories, N. Y., (1.25 mg) 6 wk before study.
Metabolic balance determinations were performed according to the principles outlined by Reifenstein, Albright, and Wells (3) and Furman, Howard, Wells, and MacAulay (4) . To achieve conditions as ideal as possible, drugs which might interfere with study, such as diuretics and hormones were discontinued except as noted. Other medications deemed necessary for the well-being of the patients were supplied from a single manufacturer's lot and were administered in constant doses throughout study.
All patients except A. V. received constant metabolic balance-diets. A. V. was given a constant calcium and low hydroxyproline diet. The ranges of daily dietary intake were 440-670 mg of calcium, 980-1150 mg of phosphorus, 12-20 mEq of magnesium, 40-85 mEq of potassium, 25 -75 mEq of sodium, and 9-12 g of total nitrogen. 5-10 dietary portions, the rare dietary rejections, and all medications were analyzed chemically during each patient's study. The daily intakes were calculated as the averages of the analytic values for the dietary portions and the administered medications minus those for the dietary rejections. The metabolic balance-studies began with a 3 day period of adjustment followed by 7-14 days of equilibration to the constant diet. After equilibration, 2 or 3 wk of control observations were followed by 4-8 wk of calcitonin administration. In one osteoporotic patient (J. M.), a 2 wk postcontrol period followed the 4 wk calcitonin period. In most patients, the gelatin vehicle was administered during the last control week. Urinary excretion of inorganic constitutents, total nitrogen, and total hydroxypyroline were determined in 7-day pooled specimens. Quantitative fecal excretion of the same constituents were determined in 7-day pooled specimens corresponding to the urine pools.
Lyophilized determined by an automated Kj eldahl micro method and total urinary hydroxyproline by an automated modification of the method of Bergman and Loxley (7, 8) , to a precision and accuracy of +2%. Individual analysis of the constant diets agreed within +5% of average values.
Radiocalcium turnover studies were performed during the control period and during the 4th to 7th wk of calcitonin therapy. 50 /ACi of 47Ca (Cambridge Nuclear Corp., Cambridge, Mass.) was injected intravenously under basal conditions between 8:00 and 9:00 a.m. During the following 12 hr, multiple heparinized-blood samples were obtained; blood samples were taken daily thereafter for 7 days. The '7Ca content of the plasma specimens, daily urine specimens, 7-day fecal pools, and of appropriately diluted standards prepared from the injected material were measured at constant geometry in a gamma scintillation spectrometer. The isotopic data were expressed as the per cent of the total dose administered per liter of sample, and specific activities as the per cent dose per milliequivalents of calcium. Specific activity-curves were derived solely from plasma values. The data were subjected to digital computer analysis utilizing the four-compartment open model shown in Fig. 10 . Fractionaltransport coefficients among the four compartments, compartment sizes, and total-flux rates were determined by the computer analysis.
RESULTS
General. All patients, although severely affected by their disease ( Values represent decibels required for detection. A change of 15 decibels is considered significant. Seven Day Periods patients (A. W., M. B., and C. E. L.) after 6 to 17 wk of calcitonin (Table II) . In C. E. L., improvement in the lower frequencies occurred as the higher frequencies became worse. Three pagetic patients had no significant changes in the audiograms. No patient showed any change in bone conduction. Four patients had severe impingement upon the thoracic spinal cord or corda equina and resultant motor weakness and sensory changes in the lower extremities. In two of the patients with thoracic cord invovement (M. B. and A. V.), muscle atrophy was absent and marked improvement in muscle power and in the sensory deficits was evident by the 4th wk of calcitonin. After 6 wk of calcitonin, both patients left the hospital without the aid of the cane and walker which they had required at admission. One (F. J. C.) of the two patients with a corda equina lesion, sensory deficits, and severe muscle atrophy, showed a small but significant improvement in toe and ankle movements and a complete reversal of the sensory defect. The other patient (C. E. L.) did not improve neurologically. Three of the four patients with neurologic involvement also manifested subjective and objective decreases in skin temperature in the lower extremities before calcitonin and these abnormalities disappeared after 1 wk of calcitonin treatment. A detailed study of the response to calcitonin of these four patients and other pagetic patients with neurologic complications will be reported separately.
Blood data. In the patients with Paget's disease no tendency to fasting hypocalcemia was observed ( Fig. 1) and, in three courses of therapy, the fasting serum calcium rose by 0.5 to 1.5 mg per 100 ml during calcitonin. The pattern of hourly serum calcium levels between 8 a.m. and 8 p.m. was studied before therapy and during the 5th wk of calcitonin, and no differences were noted. The fasting serum inorganic phosphorus levels showed
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F. Shai, R. K. Baker, and S. Wallach FIGuRE 2 Weekly fasting serum alkaline phosphatase levels (King-Armstrong units) in the pagetic and osteoporotic patients. Format is the same as in Fig. 1 improved gastrointestinal absorption of phosphorus. In three pagetic patients, phosphorus balance was not influenced by calcitonin. Except for the natriuresis and consequent negative sodium balance in A. W., sodium balance was not significantly affected by calcitonin administration. Potassium, magnesium, and nitrogen balance were similarly unaltered.
Radiocalcium turnover (Fig. 9 ). Radiocalcium turnover, indicated by the decline in the plasma calciumspecific activity curves, was markedly accelerated in all six pagetic patients. Calcitonin reduced the rate of decline of the plasma calcium specific activity in five patients although an accelerated turnover was still evident after 4-16 wk. The turnover data were subjected to quantitation utilizing a digital computer program and a four-compartment open model (Fig. 10) limits can be set at 80 mEq, 100 mEq, and 130 mEq, respectively. As shown in Table III computer-derived parameters of radiocalcium turnover (Table III) .
In A. D., calcium balance (Fig. 11) was normal but became negative by 100 mg/day during calcitonin. Nitrogen balance also became negative by 3 g/day. In J. M., a slight tendency to positive calcium balance occurred during calcitonin, and calcium balance became distinctly positive, by 200 mg/day, after calcitonin was stopped abruptly (Fig. 12) . Phosphorus balance became slightly less positive during calcitonin in both patients. Sodium, potassium, and magnesium balances were not significantly altered. Iliac crest bone biopsies, skeletal X-rays, and subjective assessments of back and cervical pain were unchanged.
DISCUSSION
The studies performed provide clinical and metabolic evidence which supports the ability of calcitonin to reverse the skeletal manifestations of Paget's disease. Skeletal pain, bone vascularity, congestive heart failure, and neurologic impairment were variably but dramatically improved. Of the clinical effects, only the pain relief was subjective since the improvement in other clinical parameters was documented by objective changes in physical findings. Prolonged relief of pain was observed in these patients and in a series of 20 additional patients treated for several months on an outpatient basis, suggesting that pain relief is a real rather than a psychic result of calcitonin treatment.
Predominant resorption of bone, indicated by negative calcium balance, is frequently present when pagetic patients come to clinical attention. Reversal of negative calcium balance and a reduction in hydroxyprolinuria can be related directly to the anti-resorptive function of calcitonin. Although the turnover of "7Ca and the level of serum alkaline phosphatase are generally thought to reflect the rate of bone formation, these parameters were also favorably affected by calcitonin. The improvement in these two parameters is probably due to concomitant decrease in bone formation consequent to primary inhibition of bone resorption.
Bell, Avery, and Johnston (13) have reported the induction of positive or less negative calcium balance of 85-150 mg/day during daily intramuscular administration of 4-8 MRC U/kg calcitonin to patients with Paget's disease. In their report as well as in the present study, both urinary and fecal calcium decreased. On the other hand, Haddad, Birge, and Avioli (14) Seven Day Periods of Treatment FIGURE 8 Urinary calcium and total hydroxyproline excretion in pagetic patient (A. V., 75 F, Paget's disease). The patient was unable to cooperate in metabolic balance studies because of advanced age and neurologic infirmity.
The calcium and hydroxyproline content of the diet was fixed but the diet was otherwise uncontrolled. Urinary creatinine was measured daily. Each week, the two to four 24-hr urines with adequate creatinine levels were selected for analysis. The data represent averages of these two to four excretory values except during the 1st wk of calcitonin when urinary losses occurred every day. Note the decrease in urinary calcium and hydroxyproline during calcitonin administration.
daily administration of 400-1500 MRC U for a longer period, but no balance procedures were employed to assess gastrointestinal effects. In these previous studies, urinary hydroxyproline decreased during the 1st wk of calcitonin. The present data demonstrate that urinary hydroxyproline continues to decrease gradually as treatment proceeds. In studies of the immediate effects of intravenous calcitonin, Bijvoet, van der Sluys Veer, and Jansen (15, 16) showed decreases in hydroxyproline within 2 hr and, in the majority of the patients in the present report, reductions were manifest on the 1st day of calcitonin. The accumulated data also indicate that the level of serum alkaline phosphatase is a less sensitive index of response of Paget's disease to calcitonin than is urinary hydroxyproline since reductions are not evident in the early weeks of treatment. With prolonged treatment, however, the serum alkaline phosphatase almost invariably decreases. (Unpublished observations.)
The ability of calcitonin to improve net gastrointestinal absorption of calcium was noted in this series of pagetic patients and by Bell, Avery, and Johnston (13) despite previous animal studies indicating that the gastrointestinal tract is not essential for the hypocalcemic effect of calcitonin (17) . The v..5 administered calcitonin but there is no positive evidence for this contention. The phosphaturic effect of calcitonin observed in these studies has been described previously (13, 15, 16) . Thenatriuresis observed in a florid form in one patient and to a minor extent in the remainder has also been noted by others (13, 15, 16) the degree of fasting hypocalcemia, positive calcium balance, reduction in serum alkaline phosphatase-activity, urinary hydroxyproline excretion, and radiocalcium turnover induced by calcitonin. The tendency to develop slightly higher fasting serum calcium levels could also have resulted from secondary hyperparathyroidism. No measurements of circulating parathyroid hormone levels were made in these patients. However, elevation of circulating parathyroid hormone levels measured by radioimmunoassay have been found in pagetic patients given calcitonin (20) . The additional observation in two pagetic patients that lower doses of calcitonin resulted in as good or better clinical and metabolic effects than the larger dose is also compatible with the production of secondary hyperparathyroidism as an undesirable side effect of high doses. A third possibility for the variable quantitative effect of calcitonin could relate to the "escape phenomenon" observed with calcitonin in vitro (21) and in patients with high circulating levels of calcitonin due to medullary carcinoma of the thyroid who do not manifest hypocalcemia (22 In contrast to the observations in Paget's disease, the results of calcitonin administration in two patients with osteoporosis were not dramatic. Several possible reasons for the disappointing results may be cited. The radiocalcium turnover studies suggest that skeletal turnover was moderately slow in both patients and calcitonin may be relatively inactive in such situations (23) .
Second, one patient was on estrogen therapy throughout study whereas the other patient had recently discontinued estrogen. In rats, estradiol has been found capable of antagonizing the hypocalcemic action of calcitonin (24; F. Shai, and S. Wallach, manuscript in preparation), suggesting that a similar ability to inhibit calcitonin might occur in humans receiving estrogens. Lastly, the induction of secondary hyperparathyroidism might have completely overriden the positive effects of the calcitonin. Patient A. D. developed sustained hypocalcemia and subsequently developed negative calcium and nitrogen balance, findings which are similar to those observed in hyperparathyroidism (25) . The observations in osteoporosis should not be taken as evidence of inefflcacy of calcitonin. Lower doses of calcitonin combined with high calcium, magnesium, and/or phosphorus intake might forestall secondary hyperparathyroidism, stimulate bone formation, or enhance the endorgan action of the calcitonin.
The relatively negative data in osteoporosis further highlight the efficacy of calcitonin in ameliorating the clinical and metabolic manifestations of Paget's disease. In studies in progress, it has also been found that outpatient treatment with calcitonin by self-injection, using single daily subcutaneous doses of 100-200 MRC U is equally efficacious. Continuous treatment for more than 6 months has not caused allergic reactions, side effects, or evidence of antibody formation or loss of therapeutic potency. If long term control of this previously untreatable disease can be achieved with calcitonin, the possibility that early therapy might prevent the serious concomitants of the generalized condition becomes an intriguing prospect.
